Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.21 USD | +3.55% | +6.64% | +13.03% |
Feb. 14 | Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024 | |
Feb. 14 | Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M | MT |
Financials (USD)
Sales 2024 * | 83.55M | Sales 2025 * | 77.08M | Capitalization | 17.26M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | 2M | EV / Sales 2024 * | 0.21 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.22 x |
P/E ratio 2024 * |
-1.39
x | P/E ratio 2025 * |
6.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.51% |
Latest transcript on Aytu BioPharma, Inc.
1 day | +3.55% | ||
1 week | +6.64% | ||
Current month | +14.23% | ||
1 month | -4.46% | ||
3 months | +11.85% | ||
6 months | +12.24% | ||
Current year | +13.03% |
Managers | Title | Age | Since |
---|---|---|---|
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 15-04-15 |
Jarrett Disbrow
FOU | Founder | 49 | 15-04-15 |
Mark Oki
DFI | Director of Finance/CFO | 55 | 22-01-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Vivian Liu
BRD | Director/Board Member | 62 | 22-06-30 |
Jarrett Disbrow
FOU | Founder | 49 | 15-04-15 |
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 15-04-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 3.1 | +1.31% | 6,093 |
24-05-07 | 3.06 | 0.00% | 5,914 |
24-05-06 | 3.06 | +1.66% | 43,666 |
24-05-03 | 3.01 | 0.00% | 21,150 |
24-05-02 | 3.01 | +4.04% | 7,349 |
Delayed Quote Nasdaq, May 09, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.03% | 17.26M | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |
- Stock Market
- Equities
- AYTU Stock